Kinnate Biopharma Inc. to Participate in Upcoming Investor Conferences
2023年6月2日 - 5:05AM
Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage
precision oncology company, today announced that the company will
participate in two upcoming investor conferences:
- Wednesday, June 7 at 2:30 p.m. ET / 11:30 a.m. PT at the
Jefferies Healthcare Conference. Neha Krishnamohan, chief financial
officer and executive vice president, corporate strategy, will
represent the company in a fireside chat at the conference.
- Thursday, June 15 at 12:20 p.m. ET / 9:20 a.m. PT at the
Goldman Sachs 44th Annual Global Healthcare Conference. Nima
Farzan, chief executive officer, will represent the company in a
fireside chat at the conference.
Members of the Kinnate management team will also host investor
meetings during the conferences.
Investors and the general public are invited to listen to a live
webcast of the session through the "Investors and Media" section on
Kinnate.com. A webcast replay will be made available following the
event for 90 days.
About Kinnate Biopharma Inc.
Kinnate Biopharma Inc. is a clinical-stage precision oncology
company focused on expanding on the promise of targeted therapies
for those battling cancer. The company is developing medicines for
known oncogenic drivers where there are no approved targeted drugs
and to overcome the limitations of marketed cancer therapies, such
as non-responsiveness or acquired and intrinsic resistance. Kinnate
has two lead clinical programs being studied in solid tumors with
RAF, NRAS and FGFR-driven alterations, and is rapidly progressing a
pipeline of additional small molecule drug candidates as part of
the Kinnate Discovery Engine. The company is driven by the urgency
and knowledge that patients are waiting for new, effective cancer
medicines. For more information, visit Kinnate.com and follow us on
LinkedIn.
Forward Looking Statements
This press release contains forward-looking statements that
involve substantial risks and uncertainties. These risks,
uncertainties, assumptions and other factors are described under
the heading “Risk Factors” in our Quarterly Report on Form 10-Q for
the quarter ended March 31, 2023 that we have filed with the
Securities and Exchange Commission (SEC), as well as in our
subsequent filings we make with the SEC. New risk factors emerge
from time to time and it is not possible for our management to
predict all risk factors, nor can we assess the impact of all
factors on our business or the extent to which any factor, or
combination of factors, may cause actual results to differ
materially from those contained in, or implied by, any
forward-looking statements. Investors should not rely upon
forward-looking statements as predictions of future events.
Although we believe that the expectations reflected in the
forward-looking statements are reasonable, we cannot guarantee
future results, levels of activity, performance or achievements.
Our forward-looking statements speak only as of the date of this
release, and except as required by law, we undertake no obligation
to update publicly any forward-looking statements for any reason in
the future.
Investor & Media Contact:
Priyanka Shah | Priyanka.Shah@kinnate.com | +1-908-447-6134
Kinnate Biopharma (NASDAQ:KNTE)
過去 株価チャート
から 4 2024 まで 5 2024
Kinnate Biopharma (NASDAQ:KNTE)
過去 株価チャート
から 5 2023 まで 5 2024